General description
A semi-synthetic form of Paclitaxel (Cat. No. 580555) having no contamination by natural taxanes. Also has reduced levels of epimerization products as contaminants.
A semi-synthetically derived form of Paclitaxel (TAXOL®, Cat. No. 580555) having no contamination of natural taxanes. Also has less epimerization products as contaminants. Promotes assembly of microtubules and inhibits tubulin disassembly. An effective agent in blocking HeLa and B16 cells at the G2/M stage. Inhibits DNA synthesis and stimulates the release of tumor necrosis factor-α. Induces apoptosis in murine mammary carcinoma MCA-4 and ovarian carcinoma OCA-1 tumors.
Biochem/physiol Actions
Cell permeable: no
Primary Target
Promotes assembly of microtubules and inhibits tubulin disassembly.
Product does not compete with ATP.
Reversible: no
Warning
Toxicity: Carcinogenic / Teratogenic (D)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
Other Notes
Derry, W.B., et al. 1995. Biochemistry 34, 2203.
Milas, L., et al. 1995. Cancer Chemother. Pharmacol.35, 297.
Donaldson, K.L., et al. 1994. Int. J. Cancer 57, 847.
Hornback, N.B., et al. 1994. In Vivo8, 819.
Manthey, C.L., et al. 1992. J. Immunol. 149, 2459.
Rowinsky, E.K., et al. 1992. Semin. Oncol.19, 646.
Ding, A.H., et al. 1990. Science248, 370.
Mogensen, M.M. and Tucker, J.B. 1990. J. Cell Sci.97, 101.
Slichenmeyer, W.J. and Von Hoff, D.D. 1990. J. Clin. Pharmacol. 30, 770.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Taxol is a registered trademark of Bristol-Myers Squibb Co.
- UPC:
- 51286505
- Condition:
- New
- Weight:
- 1.00 Ounces
- HazmatClass:
- No
- WeightUOM:
- LB
- MPN:
- 580556-5MG
